Core Insights - Senseonics Holdings (SENS) shares increased by 5.3% to close at $7.33, supported by high trading volume, and have gained 26.1% over the past four weeks [1][2] Company Performance - The company achieved CE Mark approval for the Eversense 365 continuous glucose monitoring (CGM) system, which is the first one-year CGM and can integrate with compatible medical devices [2] - Senseonics is expected to report a quarterly loss of $0.43 per share, reflecting a year-over-year decline of 7.5%, while revenues are projected to be $14.2 million, representing a 71.1% increase from the previous year [3] Earnings Estimates - The consensus EPS estimate for Senseonics has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4]

Key Takeaways SENS shares gain 2.1% after securing European CE Mark approval for the Eversense 365 CGM.Senseonics gains a one-year implantable CGM in Europe, expanding its addressable market beyond the U.S.SENS holds full commercialization rights and integration potential, supporting revenue visibility.Senseonics Holdings, Inc. (SENS) recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system.The approval builds on the U ...

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system. Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the count ...

GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah. To request a meeting with Senseonics, investors should co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2026 SENSEONICS HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37717 47-1210911 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer FORM 8-K Identification No.) 20451 Seneca Meadows Parkway Germantown, MD 20876-7005 (Addre ...

Preliminary unaudited revenue expected to be approximately $14.2 million for Q4 2025, an increase of 71% year-over-year Introduced 2026 revenue guidance of $58-$62 million Expects to report fourth quarter and full year 2025 financial results on March 2, 2026 GERMANTOWN, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with d ...

Core Insights - Senseonics Holdings, Inc. (SENS) has achieved a significant commercialization milestone with the launch of the Eversense 365 continuous glucose monitor (CGM) integrated with the twiist automated insulin delivery (AID) system, marking the first pairing of a one-year, implantable CGM with an AID platform [2][3][7] Company Developments - The integration with Sequel MedTech enhances diabetes management by reducing sensor changes and enabling automated insulin adjustments, with broader availability expected by March 2026 [3][10] - The Eversense 365's implantable design allows for uninterrupted glucose monitoring for up to one year, addressing common issues associated with frequent sensor changes [9] - SENS reported a strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million year-over-year, driven by a 160% increase in new patient growth in the U.S. [12] - The company achieved a gross profit of $3.5 million in the quarter, a significant improvement from a gross loss of $4.1 million a year ago, indicating progress in cost structure and operating efficiency [14] Market Position and Trends - Following the announcement of the Eversense 365 launch, SENS shares gained 8%, although they have declined 28.8% over the past six months compared to a 10.5% decline in the industry [4] - The global blood glucose monitoring devices market is projected to grow from $15.53 billion in 2025 to $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033, driven by the increasing prevalence of diabetes [11]

GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM systems for people with diabetes with Sequel MedTech, LLC, a company developing state-of-the-art insulin delivery technologies, have launched the integration of their products with the first patients having received a Sequel twiist AID system paired with the Eversense 365 CGM. The commercial lau ...

Senseonics Holdings ( SENS ) has been developing CGM devices that are far superior to any devices offered by its competitors. Those innovative efforts are yet to yield returns for shareholders. The one major criticismFull-time Equity Analyst and part-time retail investor with a bias for high quality stocks trading at discounted prices. over the past 5 years I've been retail investing and learning more about how the stock market works, following the work of Ben Graham and Joel Greenblatt. Equity Markets are ...

A group of nine U.S. lawmakers sent a letter to U.S. Secretary of Defense Pete Hegseth this week urging the Pentagon to add a slew of Chinese technology firms to a list of entities allegedly assisting... ...